精神病中的抗胆碱能负荷与认知功能:一项系统综述与Meta分析
该系统综述与Meta分析检索MEDLINE、Embase和PsycINFO从建库至2023年10月的文献,纳入40项研究(抗胆碱能负荷研究25项、4620例;血清抗胆碱能活性研究6项、382例;减量研究9项、186例),发现抗胆碱能负荷与整体认知及多个认知域呈负相关,减量抗胆碱能药物可改善言语学习、工作记忆和执行功能,但作者指出需要随机临床试验来无偏地量化获益。
要点
- 抗胆碱能负荷与精神病患者整体认知呈负相关(r=-0.37,95%CI=-0.48,-0.25)。
- 减量抗胆碱能药物可改善言语学习(d=0.77,95%CI=0.44,1.1)、工作记忆(d=0.94,95%CI=0.63,1.26)和执行功能(d=0.44,95%CI=0.26,0.62)。
- 作者认为,从临床角度看,减量抗胆碱能药物可能改善精神病患者的认知,但需要随机临床试验来无偏地量化获益。
核心结论
- 抗胆碱能负荷与精神病中观察到的认知损害相关。
- 从临床角度看,减量抗胆碱能药物可能改善精神病患者的认知。
- 然而,需要随机临床试验来无偏地量化获益。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase和PsycINFO从建库至2023年10月,纳入报告客观认知评估和抗胆碱能负荷量化(临床量表、血清抗胆碱能活性或抗胆碱能药物减量)的研究。
- 共纳入40项研究:25项抗胆碱能负荷研究(4620例患者)、6项血清抗胆碱能活性研究(382例患者)、9项减量研究(186例患者)。
- 分析在R中使用metafor包进行,采用随机效应Meta分析模型,并评估异质性、研究质量和Meta回归(年龄、性别和抗精神病药剂量按氯丙嗪等效剂量)。
主要发现
- 抗胆碱能负荷与整体认知呈负相关(r=-0.37,95%CI=-0.48,-0.25),与言语学习(r=-0.28,95%CI=-0.36,-0.21)、视觉学习(r=-0.17,95%CI=-0.28,-0.06)、工作记忆(r=-0.22,95%CI=-0.29,-0.14)、处理速度(r=-0.24,95%CI=-0.35,-0.13)、注意力(r=-0.19,95%CI=-0.29,-0.08)、执行功能(r=-0.17,95%CI=-0.27,-0.06)和社交认知(r=-0.12,95%CI=-0.19,-0.05)也呈负相关。
- 血清抗胆碱能活性与言语学习(r=-0.26,95%CI=-0.38,-0.14)、工作记忆(r=-0.19,95%CI=-0.35,-0.03)和执行功能(r=-0.16,95%CI=-0.27,-0.04)呈负相关。
- 减量抗胆碱能药物改善了言语学习(d=0.77,95%CI=0.44,1.1)、工作记忆(d=0.94,95%CI=0.63,1.26)和执行功能(d=0.44,95%CI=0.26,0.62)的评分。
临床怎么用
- 作者认为,从临床角度看,减量抗胆碱能药物可能改善精神病患者的认知。
- 作者指出,需要随机临床试验来无偏地量化减量抗胆碱能药物带来的获益。
局限性
- 需要随机临床试验来无偏地量化减量抗胆碱能药物带来的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors synthesized evidence from studies quantifying the relationship between anticholinergic medication and cognitive function in psychosis, and additionally explored studies that investigated whether reducing anticholinergic medications affects cognitive function in individuals with psychosis. METHODS: A database search was conducted in MEDLINE, Embase, and PsycINFO, from database inception to October 2023, for studies reporting objective cognitive assessment and quantification of anticholinergic burden using clinical scales, serological anticholinergic activity, or tapering of anticholinergic medications. Analyses were carried out in R using the metafor package. Random-effects meta-analysis models were employed, along with assessment of heterogeneity, study quality, and meta-regressions (age, sex, and antipsychotic dosage in chlorpromazine equivalents). RESULTS: Of 1,337 citations retrieved, 40 met inclusion criteria, comprising 25 anticholinergic burden studies (4,620 patients), six serological anticholinergic activity studies (382 patients), and nine tapering studies (186 patients). A negative correlation was identified between anticholinergic burden and global cognition (r=-0.37, 95% CI=-0.48, -0.25), verbal learning (r=-0.28, 95% CI=-0.36, -0.21), visual learning (r=-0.17, 95% CI=-0.28, -0.06), working memory (r=-0.22, 95% CI=-0.29, -0.14), processing speed (r=-0.24, 95% CI=-0.35, -0.13), attention (r=-0.19, 95% CI=-0.29, -0.08), executive functions (r=-0.17, 95% CI=-0.27, -0.06), and social cognition (r=-0.12, 95% CI=-0.19, -0.05), and between serological anticholinergic activity and verbal learning (r=-0.26, 95% CI=-0.38, -0.14), working memory (r=-0.19, 95% CI=-0.35, -0.03), and executive functions (r=-0.16, 95% CI=-0.27, -0.04). Finally, tapering off anticholinergic medication improved the scores in verbal learning (d=0.77, 95% CI=0.44, 1.1), working memory (d=0.94, 95% CI=0.63, 1.26), and executive functions (d=0.44, 95% CI=0.26, 0.62). CONCLUSIONS: Anticholinergic burden is associated with the cognitive impairments observed in psychosis. From a clinical perspective, tapering off anticholinergic medication in patients with psychosis may improve cognition. However, randomized clinical trials are needed for an unbiased quantification of benefit.
引用
- Mancini V, Latreche C, Fanshawe JB, et al. Anticholinergic Burden and Cognitive Function in Psychosis: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2025. PMID: 40007252. doi:10.1176/appi.ajp.20240260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。